Medeikon

Medeikon was a medical technology company that specialized in the development of advanced optical imaging systems for cardiovascular diagnostics. The company's core technology was Spectroscopic Optical Coherence Tomography (SOCT), which combined high-resolution cross-sectional imaging with spectroscopic analysis to characterize tissue composition. This platform was specifically designed to identify "vulnerable" plaques—lipid-rich arterial deposits at high risk of rupture—which are a primary cause of acute myocardial infarction. By providing clinicians with detailed information on plaque morphology and chemical makeup, Medeikon aimed to improve risk stratification and treatment planning for patients with coronary artery disease. The company was founded on research from the Massachusetts Institute of Technology and the University of Illinois. Although it successfully conducted early clinical studies, the company is no longer active.